Abstract: The present disclosure relates to methods for treating pancreatic ductal adenocarcinoma comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.

Abstract: The present disclosure provides methods of treating cancer or light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject and the uses thereof.

Abstract: Disclosed herein are methods and compositions for the treatment of movement disorders including neuromuscular disorders, muscular injuries, and spasticity-associated conditions. Methods of treatment include reducing skeletal muscle contractions to reduce muscle damage by inhibiting skeletal muscle myosin II.

Abstract: Various antibody construct compositions are disclosed. The compositions of antibody construct-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and used of the antibody construct-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer. A genus of STING agonist compounds and method of synthesis is also disclosed.

Abstract: Disclosed herein are methods and compositions for the treatment of movement disorders including neuromuscular disorders, muscular injuries, and spasticity-associated conditions. Methods of treatment include reducing skeletal muscle contractions to reduce muscle damage by inhibiting skeletal muscle myosin II.

Abstract: Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGF?R1, TGF?R2, TNKS, TNIK, or mTOR.

Abstract: Various antibody construct compositions are disclosed. The compositions of antibody construct-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and used of the antibody construct-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer. A genus of STING agonist compounds and method of synthesis is also disclosed.

Abstract: Various antibody construct compositions are disclosed. The compositions of antibody construct-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and used of the antibody construct-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer.

Abstract: ROR2 is provided as a therapeutic target and prognostic marker for cancers, which include without limitation specific carcinomas and sarcomas. This invention also provides for the use of conjugates comprising an antibody that recognizes and binds ROR2, and a cytotoxic agent. In the cytotoxic conjugates, the cell binding agent has a high affinity for ROR2 and the cytotoxic agent has a high degree of cytotoxicity for cells expressing ROR2, such that the cytotoxic conjugates of the present invention form effective killing agents. In a preferred embodiment, the cell binding agent is an anti-ROR2 antibody or an epitope-binding fragment thereof, more preferably a humanized anti-ROR2 antibody or an epitope-binding fragment thereof, wherein a cytotoxic agent is covalently attached, directly or via a cleavable or non-cleavable linker, to the antibody or epitope-binding fragment thereof.